Other articles

Photo by Pavel Danilyuk from Pexels

Spruce Biosciences Soars With BTD For MPS IIIB Therapy TA-ERT

Photo by Tima Miroshnichenko from Pexels

MoonLake Posts Mixed Data For Sonelokimab For Patients With Hidradenitis Suppurativa

Photo by Edward Jenner from Pexels

Positive 3-Year AMT-130 Data For Huntington’s From uniQure Bodes Well For Pre-BLA Meeting

Photo by Artem Podrez from Pexels

Pfizer Acquires Metsera For $7.3 Billion For Differentiated Weight Loss Drug

Photo by Tima Miroshnichenko from Pexels

Kairos Posts Positive Interim Prostate Cancer Treatment Resistance Data With ENV105

Photo by MART PRODUCTION from Pexels

aTyr Pharma Fails Primary Endpoint In Lung Disorder Study, But Plans Talks With FDA

Photo by Ivan Samkov

Gri Posts Interim IPF Treatment Data With NKT Cell Antagonist GRI-0621

Photo by Tima Miroshnichenko

Travere Gets Welcomed News For Kidney Disease Therapy FILSPARI

Photo by Pavel Danilyuk from Pexels

Novartis To Acquire Tourmaline Bio For $1.4B For Novel IL-6 Inhibitor Pacibekitug

Photo by Edward Jenner from Pexels

Rapport’s Positive Seizure Data With RAP-219 Could Lead To Phase 3 Program Initiation

Photo by Tima Miroshnichenko from Pexels

Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Photo by Pavel Danilyuk from Pexels

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Photo by Polina Tankilevitch from Pexels

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Photo by Tima Miroshnichenko from Pexels

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Photo by Mikhail Nilov from Pexels

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

Photo by Martin Lopez from Pexels

One Patient Death Due To Kidney Injury In CytomX’s Ongoing Development Of CX-2051

Photo by Pavel Danilyuk from Pexels

ORIC Reduces Workforce by 20% But Set To Tackle Two Late-Stage Programs In 2026

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Novartis Scores Huge Win In Sjögren’s disease With Dual Action Monoclonal Antibody Ianalumab

Bicycle Reduces 25% Of Staff Amid Second Half Of 2025 Program Updates Expected

Scroll to Top